DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Factive (Gemifloxacin Mesylate) - Published Studies

 
 



Factive Related Published Studies

Well-designed clinical trials related to Factive (Gemifloxacin)

Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial. [2011.02]

Bioequivalence evaluation of 320 mg gemifloxacin tablets in healthy volunteers. [2007.11]

Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. [2004.08]

A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. [2004.08]

Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones. [2004.02]

Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. [2003.03]

Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. [2002.11]

Cost-effectiveness of gemifloxacin: results from the GLOBE study. [2002.07.15]

Short treatment durations for acute bacterial rhinosinusitis: Five days of gemifloxacin versus 7 days of gemifloxacin. [2002.07]

A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. [2002.04]

Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. [2001.12]

Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. [2001.09]

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. [2001.07]

Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin. [2001.06]

Impact of gemifloxacin on the normal human intestinal microflora. [2001.02]

Effects of single oral doses of gemifloxacin (320 milligrams) versus trovafloxacin (200 milligrams) on fecal flora in healthy volunteers. [2001.02]

Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. [2001.02]

The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. [2000.09]

Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group. [2000.08]

The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. [2000.08]

Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin. [1999.11]

Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers. [1999.11]

Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. [1999.11]

Well-designed clinical trials possibly related to Factive (Gemifloxacin)

Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. [2008.12.02]

Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. [2008.12.02]

Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases. [2003.10]

Time course of recovery of health status following an infective exacerbation of chronic bronchitis. [2003.07]

Other research related to Factive (Gemifloxacin)

Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial. [2015]

The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. [2014]

Twenty-eight days repeated oral dose toxicity study of gemifloxacin in Wistar albino rats. [2010.11]

Convulsant activity and pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of gemifloxacin in rats. [2010.03]

[Gemifloxacin for the treatment of uncomplicated urinary infections (acute cystitis)] [2009.12]

A probable association of acute dystonia with gemifloxacin administration. [2009.12]

Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid. [2009.09]

Gemifloxacin-associated neurotoxicity presenting as encephalopathy. [2009.04]

Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis. [2009]

Role of gemifloxacin in community-acquired pneumonia. [2008.08]

Gemifloxacin for community-acquired pneumonia. [2008.05]

Role of gemifloxacin in the management of community-acquired lower respiratory tract infections. [2008.04]

Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. [2008.01]

Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. [2007.09.20]

Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. [2007.07]

Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. [2007.05.30]

Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice. [2006.12]

Cutaneous adverse events and gemifloxacin: observations from the clinical trial program. [2006.02]

Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. [2005.05]

In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. [2005.02]

Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections. [2004.12]

Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose. [2004.11]

Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. [2004.07]

Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. [2004.06]

Gemifloxacin: a new fluoroquinolone. [2004.05]

A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. [2004.05]

Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae. [2004.02]

In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone. [2003.08]

Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. [2003.07]

Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility. [2003.06]

Gemifloxacin: effects of sub-inhibitory concentrations on various factors affecting bacterial virulence. [2003.04]

In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea. [2002.12]

Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. [2002.05]

Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis. [2002.05]

In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. [2001.08]

Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. [2001.07]

Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: phase I study. [2001.06]

Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. [2001.04]

Gemifloxacin: survival of the fittest. [2000.07]

Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group. [2000.07]

Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. [2000.06]

Gemifloxacin. [2000.05]

Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection. [2000.04]

Gemifloxacin is effective in experimental pneumococcal meningitis. [2000.03]

Other possibly related research studies

Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. [2005.07]

Antimicrobial treatment of lower respiratory tract infections in the hospital setting. [2005.07]

Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. [2005]

Gateways to clinical trials. [2004.11]

[Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000)] [2004.05]

Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology. [2004.06.01]

Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. [2004.05.15]

New therapies for pneumococcal meningitis. [2004.04]

Pseudomonal infections in patients with COPD: epidemiology and management. [2003]

Short-course antimicrobial therapy of respiratory tract infections. [2003]

Treatment of bacterial skin and skin structure infections. [2003.08]

The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. [2003.08]

Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data. [2003.07]

Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. [2003.06]

Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program. [2003.05]

Maximizing efficacy and reducing the emergence of resistance. [2003.05]

In vitro antibacterial activity and pharmacodynamics of new quinolones. [2003.04]

Novel antibacterial agents for the treatment of serious Gram-positive infections. [2003.03]

In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic. [2002.09]

Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. [2002.09.01]

In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. [2002.04]

Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones. [2002.06]

Resistance among Streptococcus pneumoniae: Implications for drug selection. [2002.06.15]

[Flouroquinolones of the third and fourth generations] [2001.11]

A critical review of the fluoroquinolones: focus on respiratory infections. [2002]

Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. [2001.10]

[Third and fourth generation fluoroquinolones] [2001.10]

Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana. [2001.08]

Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. [2001]

Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. [2001.09.15]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017